JP2018513142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513142A5 JP2018513142A5 JP2017551201A JP2017551201A JP2018513142A5 JP 2018513142 A5 JP2018513142 A5 JP 2018513142A5 JP 2017551201 A JP2017551201 A JP 2017551201A JP 2017551201 A JP2017551201 A JP 2017551201A JP 2018513142 A5 JP2018513142 A5 JP 2018513142A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- subject
- cancer
- cage structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 60
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000008685 targeting Effects 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 102000005853 Clathrin Human genes 0.000 claims 4
- 108010019874 Clathrin Proteins 0.000 claims 4
- 229930193282 clathrin Natural products 0.000 claims 4
- 239000012216 imaging agent Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- CWNBRNSIRVKSDC-UHFFFAOYSA-N azonafide Chemical compound C1=CC=C2C(C(N(CCN(C)C)C3=O)=O)=C4C3=CC=CC4=CC2=C1 CWNBRNSIRVKSDC-UHFFFAOYSA-N 0.000 claims 1
- 239000005081 chemiluminescent agent Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021062630A JP2021113196A (ja) | 2015-03-31 | 2021-04-01 | 標的型薬物デリバリーのための自己集合性分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140696P | 2015-03-31 | 2015-03-31 | |
| US62/140,696 | 2015-03-31 | ||
| PCT/US2016/025290 WO2016161129A1 (en) | 2015-03-31 | 2016-03-31 | Self assembling molecules for targeted drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021062630A Division JP2021113196A (ja) | 2015-03-31 | 2021-04-01 | 標的型薬物デリバリーのための自己集合性分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513142A JP2018513142A (ja) | 2018-05-24 |
| JP2018513142A5 true JP2018513142A5 (enExample) | 2019-05-09 |
Family
ID=57007332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551201A Pending JP2018513142A (ja) | 2015-03-31 | 2016-03-31 | 標的型薬物デリバリーのための自己集合性分子 |
| JP2021062630A Pending JP2021113196A (ja) | 2015-03-31 | 2021-04-01 | 標的型薬物デリバリーのための自己集合性分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021062630A Pending JP2021113196A (ja) | 2015-03-31 | 2021-04-01 | 標的型薬物デリバリーのための自己集合性分子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180140719A1 (enExample) |
| EP (2) | EP3936121A1 (enExample) |
| JP (2) | JP2018513142A (enExample) |
| CN (1) | CN107613963A (enExample) |
| AU (1) | AU2016242920B2 (enExample) |
| CA (1) | CA2980329C (enExample) |
| HK (1) | HK1248540A1 (enExample) |
| MA (1) | MA41866A (enExample) |
| MX (2) | MX394468B (enExample) |
| WO (1) | WO2016161129A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| WO2019079767A1 (en) * | 2017-10-20 | 2019-04-25 | The General Hospital Corporation | IMMUNOTHERAPEUTIC AGENTS TARGETING MACROPHAGES |
| CA3167921A1 (en) * | 2020-01-28 | 2021-08-05 | Nanotomer, Inc. | Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo |
| JP7783632B2 (ja) * | 2020-02-13 | 2025-12-10 | イーティーエイチ・チューリッヒ | 小分子を封入するナノ粒子 |
| CN112229887B (zh) * | 2020-09-02 | 2022-07-22 | 中国科学院深圳先进技术研究院 | 一种可精准编辑酶/电极界面及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| AU757046B2 (en) | 1997-07-01 | 2003-01-30 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| GEP20032999B (en) | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| CA2349467A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
| AU2001247372A1 (en) | 2000-03-15 | 2001-09-24 | Warner Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| WO2002006213A2 (en) | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| EP1317453B1 (en) | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
| US20030049203A1 (en) * | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| NZ547481A (en) | 2003-11-19 | 2009-12-24 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CN102898364A (zh) | 2005-05-18 | 2013-01-30 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| EP2069308B1 (en) | 2006-09-12 | 2017-03-29 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Azonafide derived tumor and cancer targeting compounds |
| BRPI0806898A2 (pt) | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
| US20090035389A1 (en) * | 2007-02-23 | 2009-02-05 | Specigen Inc. | Targeted protein cages |
| PE20131210A1 (es) | 2007-12-19 | 2013-10-31 | Genentech Inc | Derivados de 5-anilinoimidazopiridina como inhibidores de mek |
| US11235062B2 (en) | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
| CN102713606A (zh) | 2009-11-13 | 2012-10-03 | 无限制药股份有限公司 | 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法 |
| WO2014141289A1 (en) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Photo - chemo composition on the basis of microcapsules with a core -shell structure |
| WO2015108783A1 (en) | 2014-01-16 | 2015-07-23 | The Brigham And Women's Hospital, Inc. | Targeted delivery of immunoregulatory drugs |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
-
2016
- 2016-03-30 MA MA041866A patent/MA41866A/fr unknown
- 2016-03-31 CN CN201680030763.8A patent/CN107613963A/zh active Pending
- 2016-03-31 AU AU2016242920A patent/AU2016242920B2/en not_active Ceased
- 2016-03-31 MX MX2017012187A patent/MX394468B/es unknown
- 2016-03-31 JP JP2017551201A patent/JP2018513142A/ja active Pending
- 2016-03-31 EP EP21178644.7A patent/EP3936121A1/en not_active Withdrawn
- 2016-03-31 HK HK18108192.9A patent/HK1248540A1/zh unknown
- 2016-03-31 EP EP16774208.9A patent/EP3277268A4/en not_active Withdrawn
- 2016-03-31 WO PCT/US2016/025290 patent/WO2016161129A1/en not_active Ceased
- 2016-03-31 CA CA2980329A patent/CA2980329C/en active Active
- 2016-03-31 US US15/563,339 patent/US20180140719A1/en not_active Abandoned
-
2017
- 2017-09-25 MX MX2022009027A patent/MX2022009027A/es unknown
-
2019
- 2019-11-25 US US16/694,437 patent/US11666664B2/en active Active
-
2021
- 2021-04-01 JP JP2021062630A patent/JP2021113196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feng et al. | Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment | |
| Tang et al. | Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? | |
| US20180055877A1 (en) | Therapeutic nanoparticles and methods thereof | |
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| ES2873600T3 (es) | Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos. | |
| KR20190025947A (ko) | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제 | |
| WO2019006371A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY | |
| Zong et al. | Bacteria and bacterial components as natural bio-nanocarriers for drug and gene delivery systems in cancer therapy | |
| JP2013503174A5 (enExample) | ||
| Zhang et al. | Dual‐Targeted Nanoparticle‐in‐Microparticle System for Ulcerative Colitis Therapy | |
| Tang et al. | Enhanced antifungal activity by Ab-modified amphotericin B-loaded nanoparticles using a pH-responsive block copolymer | |
| Li et al. | Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment | |
| Suman et al. | Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments | |
| Yan et al. | A ROS-responsive biomimetic nano-platform for enhanced chemo-photodynamic-immunotherapy efficacy | |
| JP2013508289A5 (enExample) | ||
| FI3229776T3 (fi) | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt | |
| WO2014153160A3 (en) | METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING | |
| Wang et al. | Self‐targeted co‐delivery of an antibiotic and a cancer‐chemotherapeutic from synthetic liposomes for the treatment of infected tumors | |
| Nirbhavane et al. | Lipid nanocarrier-mediated drug delivery system to enhance the oral bioavailability of rifabutin | |
| Chintapula et al. | A novel nanocomposite drug delivery system for SARS-CoV-2 infections | |
| Shen et al. | Mannosylated polydopamine nanoparticles alleviate radiation-induced pulmonary fibrosis by targeting M2 macrophages and inhibiting the TGF-β1/Smad3 signaling pathway | |
| CA2847011A1 (fr) | Schema d'administration du n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
| Zhao et al. | Dual-targeted poly (amino acid) nanoparticles deliver drug combinations on-site: an intracellular synergistic strategy to eliminate intracellular bacteria | |
| Qi et al. | Phage–nanomaterial platforms for precision antimicrobial therapy: from design to therapeutic application | |
| Lv et al. | Tumor‐Resident Intracellular Bacteria Scavenger Activated In Situ Vaccines for Potent Cancer Photoimmunotherapy |